July 3, 2019

Five fellows, four labs, three years, two countries, and a generous donation

Joesph Lebovic and the fellows


The Lebovic Fellowship program connects scientists in Israel and Ontario, leading to the validation of a new drug candidate for leukemia and the optimization of a new potential cancer vaccine

Three years ago, the Institute for Medical Research Israel-Canada (IMRIC) received a donation from Joseph and Wolf Lebovic – two brothers who are Holocaust survivors, Canadian immigrants, avid philanthropists and recently-appointed Members of the Order of Canada. Their vision was to strengthen collaboration between the outstanding researchers in Israel and those in Ontario to accelerate cancer research.

They created the Joseph and Wolf Lebovic Fellowship Program, which paired together laboratories specializing in complementary subjects. The Program’s first round of projects officially came to a successful close today and here we recognize the progress made thanks to the generous donation of the Lebovic brothers.

Developing a drug for leukemia

Israel lead researcher: Dr. Yinon Ben-Neriah, IMRIC
Israel fellows: Waleed Minzel and Eric Hung, PhD Candidates, Hebrew University of Jerusalem

Ontario lead researcher: Dr. John Dick, Princess Margaret Cancer Centre (PMCC)
Ontario fellow: Dr. Laura Garcia-Prat, Postdoctoral Fellow, PMCC

Ben-Neriah’s lab in Israel had developed a new compound and showed it may be a valuable anti-leukemia drug, but they couldn’t explain why the drug was only effective in animal models that had strong immune systems. Understanding the relationship between the drug and the immune system would allow them to validate which leukemia subtypes would respond to their therapeutic approach.

John Dick’s lab had developed the gold standard for evaluating the efficacy of leukemia drugs in animal models using sophisticated patient-derived xenograft mouse models. Through this fellowship, the Ben-Neriah Lab teamed up with the Dick lab to learn from their expertise and gain insights into their experimental models.

Continue reading – Five fellows, four labs, three years, two countries, and a generous donation

January 4, 2018

Study shows virus-boosted immunotherapy can be effective against aggressive breast cancer

The Maraba virus is seen under an electron microscope

Researchers at The Ottawa Hospital and the University of Ottawa have found that a combination of two immunotherapies – oncolytic viruses and checkpoint inhibitors – was successful in treating triple-negative breast cancer in mouse models. Triple-negative breast cancer is the most aggressive and hard-to-treat form of the disease.

Continue reading – Study shows virus-boosted immunotherapy can be effective against aggressive breast cancer

October 11, 2017

Ontario start-up makes major deal to develop cancer-fighting viruses

Partners congratulate Turnstone Biologics

Canadian academic institutions and research organizations are congratulating Turnstone Biologics on a new partnership with AbbVie to develop cancer-fighting viruses (also called oncolytic viral immunotherapies).

Turnstone was founded in Ottawa based on research led by Dr. John Bell (from The Ottawa Hospital and uOttawa), Dr. Brian Lichty (from McMaster University) and Dr. David Stojdl (from the Children’s Hospital of Eastern Ontario and uOttawa). The Ontario Institute for Cancer Research (OICR) and BioCanRx have also played a key role in advancing the technology.

Quick Facts and Links

  • Turnstone was recently recognized as one of the top 15 biotech start-ups in the world.
  • In 2016, Turnstone secured US$41 million in venture capital (VC) funding. This is believed to be the largest VC deal in Ottawa since 2013 and the second largest biotech VC deal in Canada in 2016.
  • As of October 2017, Turnstone had 25 employees in Ottawa, Hamilton and New York. It expects to approximately double its employees by the end of next year.
  • Turnstone’s most advanced product is called Ad-MG1-MAGEA3. It is produced in The Ottawa Hospital’s Biotherapeutics Manufacturing Centre and the McMaster Immunology Research Centre.
  • Top journal Science called cancer immunotherapy the “breakthrough of the year” in 2013.
  • Ad-MG1-MAGEA3 is currently being tested in clinical trials at several hospitals across Canada. People who are interested in participating in these trials can read these frequently asked questions.
  • While public funding is crucial for cancer research discoveries, private investment is almost always necessary to advance the development of new therapies, as this can cost more than US$2.5 billion.
  • Turnstone was co-founded by FACIT, The Ontario Institute for Cancer Research’s commercialization partner, which provided initial management, seed financing, intellectual property consolidation and hiring of initial employees including the CEO.
  • Numerous organizations have supported the research team, including the Alliance for Cancer Gene Therapy, Angels of Hope, BioCanRx, the Canada Foundation for Innovation, the Canadian Cancer Society Research Institute, the Canadian Institutes of Health Research, CHEO Foundation, Hair Donation Ottawa, the Ontario Institute for Cancer Research, the Ontario Ministry of Research, Innovation and Science, The Ottawa Hospital Foundation, the Ottawa Regional Cancer Foundation and the Terry Fox Research Institute.

Continue reading – Ontario start-up makes major deal to develop cancer-fighting viruses

July 11, 2017

How OICR is helping to boost the body’s ability to fight cancer

Oncology Viruses - Image of a cell.

The body’s immune system is incredibly powerful. Its ability to detect and destroy various pathogens makes it central to maintaining good health. While we all know the role it plays in fighting the common cold or flu, many do not know that it has recently been enlisted by scientists in the fight against cancer. Researchers in a field known as immuno-oncology are working to find ways to turn on the body’s defences to locate and destroy tumour cells. OICR recently established a team of expert scientists and clinicians to develop and test new immunotherapies to help patients.

Continue reading – How OICR is helping to boost the body’s ability to fight cancer